Genetic Signatures

Genetic Signatures Interest Expense

The Interest Expense of Genetic Signatures (GSS.AX) as of Nov 5, 2026 is -211,000.00 AUD. In the previous year, Interest Expense was -141,000.00 AUD — a change of 49.65% (lower).

Interest Expense

-211,000.00AUD

YoY

49.65%

Last updated:

Interest Expense of Genetic Signatures is 2025 -211,000.00 AUD. Interest Expense of Genetic Signatures was 2024 -141,000.00 AUD. It decreases by 49.65% lower compared to the previous year.

The Genetic Signatures Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-500.00 AUD
Jan 1, 2019
-500.00 AUD
Jan 1, 2020
-166,000.00 AUD
Jan 1, 2021
-107,000.00 AUD
Jan 1, 2022
-111,000.00 AUD
Jan 1, 2023
-125,000.00 AUD
Jan 1, 2024
-141,000.00 AUD
Jan 1, 2025
-211,000.00 AUD
The Genetic Signatures Interest Expense history
YEARInterest ExpenseYoY
-211,000.00AUD+49.65%
-141,000.00AUD+12.80%
-125,000.00AUD+12.61%
-111,000.00AUD+3.74%
-107,000.00AUD-35.54%
-166,000.00AUD+33,100.00%
-500.00AUD0.00%
-500.00AUD+25.00%
-400.00AUD-63.64%
-1,100.00AUD+120.00%
-500.00AUD-99.83%
-290,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Interest Expense of Genetic Signatures is -211,000.00 AUD in 2025.

Interest Expense of Genetic Signatures changed from -141,000.00 AUD to -211,000.00 AUD, representing a 49.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genetic Signatures

All Key Metrics — Genetic Signatures